265652-38-8

Basic information

• Product Name: methyl 4-bromo-3-methylthiophene-2-carboxylate
• Synonyms: methyl 4-bromo-3-methylthiophene-2-carboxylate;4-bromo-3-methyl-2-Thiophenecarboxylic acid methyl ester;4-Bromo-3-methyl-thiophene-2-carboxylic acid methyl ester
• CAS NO: 265652-38-8
• Molecular Formula: C₇H₇BrO₂S
• Molecular Weight: 235.09828
• EINECS: -0
• Mol File: 265652-38-8.mol

Chemical Properties

• Melting Point: 61-61.5 °C
• Boiling Point: 263.3±35.0 °C(Predicted)
• Appearance: /
• Density: 1.575±0.06 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• CAS DataBase Reference: methyl 4-bromo-3-methylthiophene-2-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 4-bromo-3-methylthiophene-2-carboxylate(265652-38-8)
• EPA Substance Registry System: methyl 4-bromo-3-methylthiophene-2-carboxylate(265652-38-8)

Safety Data

• Hazardous Substances Data: 265652-38-8(Hazardous Substances Data)

Upstream product

• 265652-39-9 3-methyl-4-bromo-2-thiophenecarboxylic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 5118-06-9 methyl 3-hydroxy-2-thiophenecarboxylate 
• 863906-40-5 methyl 4-bromo-3-([(trifluoromethyl)sulfonyl]oxy)-2-thiophenecarboxylate 
• 13061-96-6 dihydroxy-methyl-borane 
• 95201-93-7 methyl 3-hydroxy-4-bromo-2-thiophenecarboxylate 
• 23806-24-8 3-methyl-2-thiophenecarboxylic acid 
• 81452-54-2 methyl 3-methylthiophene-2-carboxylate 
• 186581-53-3 diazomethane 

Downstream Products

• 1373940-62-5 4-bromo-N-(2,6-difluorophenyl)-3-methylthiophene-2-carboxamide 
• 265652-39-9 3-methyl-4-bromo-2-thiophenecarboxylic acid 
• 1398414-42-0 C₁₉H₁₇NO₃S 

Relevant articles and documents

MALT1 MODULATORS AND USES THEREOF

Provided herein are compounds, compositions, and methods useful for modulating MALT1 and for treating related diseases, disorders, and conditions.

DNDI-6148: A Novel Benzoxaborole Preclinical Candidate for the Treatment of Visceral Leishmaniasis

Visceral leishmaniasis (VL) is a parasitic disease endemic across multiple regions of the world and is fatal if untreated. Current therapies are unsuitable, and there is an urgent need for safe, short-course, and low-cost oral treatments to combat this ne

METHODS OF TREATING NEURODEGENERATIVE DISEASES

Described herein are methods of treating or preventing an ASK1 or DYRK1A associated disease, disorder, or condition comprising administering to a subject in need thereof a dual inhibitor of ASK1 and DYRK1A; including administering pharmaceutically acceptable salts and solvates thereof.

ASK1 INHIBITOR COMPOUNDS AND USES THEREOF

Described herein are compounds, including pharmaceutically acceptable salts and solvates thereof, methods of making such compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat non-alcoholic steatohepatitis and other diseases characterized by dysfunctional tissue healing and fibrosis.

COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF

The present invention provides compounds that modulate protein function, to restore protein homeostasis, including cytokine, CK1α, GSPT1, aiolos, and/or ikaros activity, and cell-cell adhesion. The invention provides methods of modulating protein-mediated diseases, such as cytokine-mediated diseases, disorders, conditions, or responses. Compositions, including in combination with other cytokine and inflammatory mediators, are provided. Methods of treatment, amelioration, or prevention of diseases, disorders, or conditions associated with a protein, such as diseases, disorders, and conditions associated with cytokines, including inflammation, fibromyalgia, rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, inflammatory bowel diseases, Crohn's disease, ulcerative colitis, uveitis, inflammatory lung diseases, chronic obstructive pulmonary disease, Alzheimer's disease, and cancer, are provided.

3-(PYRIDIN-3-YL)-ACRYLAMIDE AND N-(PYRIDIN-3-YL)-ACRYLAMIDE DERIVATIVES AND THEIR USE AS PAK OR NAMPT MODULATORS

The invention generally relates to cyclic compounds and, more particularly, to a compound represented by Structural Formula I: or a pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the multicyclic compounds. The invention also relates to a method for treating a disease or disorder selected from cancer (e.g., lymphoma, such as mantle cell lymphoma), a neurodegenerative disease, an inflammatory diseases or an immune system disease (e.g., a T- Cell mediated autoimmune diseases) in a subject in need thereof. The method comprises administering to a subject in need thereof a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof, or a composition comprising a compound of the invention, or a pharmaceutically acceptable salt thereof.

OXAZOLE AND ISOXAZOLE CRAC MODULATORS

The present invention relates to compounds of Formula (I) along with processes for their preparation that are useful for treating, preventing and/or managing the diseases, disorders, syndromes or conditions associated with the modulation of CRAC. The invention further relates to methods of treating, preventing managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of CRAC of Formula (I).

NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT

A method of treating atherosclerosis and related conditions using compounds of formula I: as well as pharmaceutically acceptable salts and solvates is disclosed. The compounds are useful for treating dyslipidemias, and in particular, reducing serum LDL, V

BENZOAZEPIN-OXY-ACETIC ACID DERIVATIVES AS PPAR-DELTA AGONISTS USED FOR THE INCREASE OF HDL-C, LOWER LDL-C AND LOWER CHOLESTEROL

The invention is directed to compounds of Formula (I) useful as PPAR agonists. Pharmaceutical compositions and methods of treating one or more conditions including, but not limited to, diabetes, nephropathy, neuropathy, retinopathy, polycystic ovary syndr

Novel thienopyridine compounds, and methods of use thereof

The present invention relates to novel compounds capable of modulating the stability and/or activity of hypoxia inducible factor (HIF).